Mai Capital Management Lineage Cell Therapeutics, Inc. Transaction History
Mai Capital Management
- $13.2 Billion
- Q4 2024
A detailed history of Mai Capital Management transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Mai Capital Management holds 657,679 shares of LCTX stock, worth $348,569. This represents 0.0% of its overall portfolio holdings.
Number of Shares
657,679
Previous 1,674,679
60.73%
Holding current value
$348,569
Previous $1.52 Million
78.46%
% of portfolio
0.0%
Previous 0.02%
Shares
11 transactions
Others Institutions Holding LCTX
# of Institutions
135Shares Held
106MCall Options Held
22.1KPut Options Held
0-
Broadwood Capital Inc New York, NY41.7MShares$22.1 Million1.65% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$5.07 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.63MShares$4.58 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY7.24MShares$3.84 Million0.12% of portfolio
-
Defender Capital, Llc.5.96MShares$3.16 Million1.17% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $90M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...